RASSF10 exhibits tumor‑suppressing potential involving tumor proliferation, metastasis and epithelial‑mesenchymal transition in esophageal squamous cell carcinoma

Liu,Yifei; Zhu,Xiaohui; Zhang,Wenwen; Bian,Tingting; Wu,Zheng; Zhang,Jianguo; Qiu,Hongmei; Hu,Yingzi; Feng,Jia; Shi,Jiahai

doi:10.3892/or.2022.8291

RASSF10 exhibits tumor‑suppressing potential involving tumor proliferation, metastasis and epithelial‑mesenchymal transition in esophageal squamous cell carcinoma

Authors:
- Yifei Liu
- Xiaohui Zhu
- Wenwen Zhang
- Tingting Bian
- Zheng Wu
- Jianguo Zhang
- Hongmei Qiu
- Yingzi Hu
- Jia Feng
- Jiahai Shi
View Affiliations

Affiliations: Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226600, P.R. China, Department of Internal Medicine, Nantong Tumor Hospital, Nantong, Jiangsu 226600, P.R. China, Department of Radiotherapy, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226600, P.R. China, Department of Respiration, Affiliated Hai'an Hospital of Nantong University, Nantong, Jiangsu 226600, P.R. China, Department of Respiration, Nantong Geriatric Rehabilitation Hospital, Branch of the Affiliated Hospital of Nantong University, Nantong, Jiangsu 226600, P.R. China, Medical School of Nantong University, Nantong, Jiangsu 226600, P.R. China, Department of Cardio‑Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226600, P.R. China
Published online on: February 22, 2022 https://doi.org/10.3892/or.2022.8291
Article Number: 80
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Growing evidence indicates that Ras‑association domain family 10 (RASSF10) is a novel tumor‑suppressor gene that is involved in the inhibition of tumor progression and metastasis; however, the biological functions and molecular mechanisms of RASSF10 in esophageal squamous cell carcinoma (ESCC) have not yet been thoroughly elucidated. The expression of RASSF10 in ESCC tissues and adjacent non‑tumor tissues was investigated employing quantitative polymerase chain reaction (qPCR) and immunohistochemistry (IHC) assays of tissue microarrays. The function of RASSF10 in ESCC cell growth, migration and invasion was determined by CCK‑8, colony formation, scratch wound healing and Transwell invasion assays, respectively. The correlation between RASSF10 and markers related to epithelial‑mesenchymal transition (EMT) was evaluated by tissue microarray (TMA)‑IHC, western blotting and immunofluorescence staining. RASSF10 was found to be highly downregulated in ESCC tissues compared with that noted in the adjacent non‑tumor tissues, and closely correlated with tumor progression and patient prognosis. Moreover, functional studies demonstrated that RASSF10 overexpression not only resulted in reduced cell growth and colony formation but also inhibited migration and invasion of the ESCC cells. Tumor RASSF10 expression was positively correlated with E‑cadherin expression and negatively correlated with vimentin. In addition, it was demonstrated that the antineoplastic functions of RASSF10 mediate inactivation of the Wnt/β‑catenin pathway in ESCC. Our findings revealed that RASSF10 may constitute a prognostic factor for ESCC patients and a crucial candidate for targeted therapy against ESCC.

View Figures

View References

1	Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, et al: Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA Oncol. 4:1221–1227. 2018. View Article : Google Scholar : PubMed/NCBI
2	Alsop BR and Sharma P: Esophageal cancer. Gastroenterol Clin North Am. 45:399–412. 2016. View Article : Google Scholar : PubMed/NCBI
3	Lou F, Sima CS, Adusumilli PS, Bains MS, Sarkaria IS, Rusch VW and Rizk NP: Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol. 8:1558–1562. 2013. View Article : Google Scholar : PubMed/NCBI
4	Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, Mark SD, Qiao YL and Taylor PR: Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 113:456–463. 2005. View Article : Google Scholar : PubMed/NCBI
5	Arnold M, Soerjomataram I, Ferlay J and Forman D: Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 64:381–387. 2015. View Article : Google Scholar : PubMed/NCBI
6	Zou S, Yang J, Guo J, Su Y, He C, Wu J, Yu L, Ding WQ and Zhou J: RAD18 promotes the migration and invasion of esophageal squamous cell cancer via the JNK-MMPs pathway. Cancer Lett. 417:65–74. 2018. View Article : Google Scholar : PubMed/NCBI
7	Richter AM, Pfeifer GP and Dammann RH: The RASSF proteins in cancer; From epigenetic silencing to functional characterization. Biochim Biophys Acta. 1796:114–128. 2009.PubMed/NCBI
8	Sherwood V, Recino A, Jeffries A, Ward A and Chalmers AD: The N-terminal RASSF family: A new group of Ras-association-domain-containing proteins, with emerging links to cancer formation. Biochem J. 425:303–311. 2009. View Article : Google Scholar : PubMed/NCBI
9	Underhill-Day N, Hill V and Latif F: N-terminal RASSF family: RASSF7-RASSF10. Epigenetics. 6:284–292. 2011. View Article : Google Scholar : PubMed/NCBI
10	Global Burden of Disease Cancer Collaboration, . Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
11	Helmbold P, Richter AM, Walesch S, Skorokhod A, Marsch WCh, Enk A and Dammann RH: RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi. J Invest Dermatol. 132(3 Pt 1): 687–694. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD, Maher ER and Latif F: The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer. 8:422009. View Article : Google Scholar : PubMed/NCBI
13	Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, Morris M, Gentle D, Chalmers AD, Maher ER and Latif F: Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene. 30:978–989. 2011. View Article : Google Scholar : PubMed/NCBI
14	Schagdarsurengin U, Richter AM, Wöhler C and Dammann RH: Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics. 4:571–576. 2009. View Article : Google Scholar : PubMed/NCBI
15	Hu X, Yu AX, Qi BW, Fu T, Wu G, Zhou M, Luo J and Xu JH: The expression and significance of IDH1 and p53 in osteosarcoma. J Exp Clin Cancer Res. 29:432010. View Article : Google Scholar : PubMed/NCBI
16	Kimura M: A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol. 16:111–120. 1980. View Article : Google Scholar : PubMed/NCBI
17	Chen Q, Yao YT, Xu H, Chen YB, Gu M, Cai ZK and Wang Z: SPOCK1 promotes tumor growth and metastasis in human prostate cancer. Drug Des Devel Ther. 10:2311–2321. 2016. View Article : Google Scholar : PubMed/NCBI
18	Cheung CT, Singh R, Kalra RS, Kaul SC and Wadhwa R: Collaborator of ARF (CARF) regulates proliferative fate of human cells by dose-dependent regulation of DNA damage signaling. J Biol Chem. 289:18258–18269. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zhang J, Zhi X, Shi S, Tao R, Chen P, Sun S, Bian L, Xu Z and Ma L: SPOCK1 is up-regulated and promotes tumor growth via the PI3K/AKT signaling pathway in colorectal cancer. Biochem Biophys Res Commun. 482:870–876. 2017. View Article : Google Scholar : PubMed/NCBI
20	Gao Y, Yi J, Zhang K, Bai F, Feng B, Wang R, Chu X, Chen L and Song H: Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 36:1612017. View Article : Google Scholar : PubMed/NCBI
21	Wang F, Feng Y, Li P, Wang K, Feng L, Liu YF, Huang H, Guo YB, Mao QS and Xue WJ: RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma. Oncotarget. 7:4279–4297. 2016. View Article : Google Scholar : PubMed/NCBI
22	Zhu R, Liu Y, Zhou H, Li L, Li Y, Ding F, Cao X and Liu Z: Deubiquitinating enzyme PSMD14 promotes tumor metastasis through stabilizing SNAIL in human esophageal squamous cell carcinoma. Cancer Lett. 418:125–134. 2018. View Article : Google Scholar : PubMed/NCBI
23	Wei Z, Chen X, Chen J, Wang W, Xu X and Cai Q: RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer. Biochem Biophys Res Commun. 432:632–637. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
25	Tarapore RS, Yang Y and Katz JP: Restoring KLF5 in esophageal squamous cell cancer cells activates the JNK pathway leading to apoptosis and reduced cell survival. Neoplasia. 15:472–480. 2013. View Article : Google Scholar : PubMed/NCBI
26	Wang F, Li P, Feng Y, Hu YL, Liu YF, Guo YB, Jiang XL, Mao QS and Xue WJ: Low expression of RASSF10 is associated with poor survival in patients with colorectal cancer. Hum Pathol. 62:108–114. 2017. View Article : Google Scholar : PubMed/NCBI
27	Lu D, Ma J, Zhan Q, Li Y, Qin J and Guo M: Epigenetic silencing of RASSF10 promotes tumor growth in esophageal squamous cell carcinoma. Discov Med. 17:169–178. 2014.PubMed/NCBI
28	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
29	Fan C, Wang W, Jin J, Yu Z and Xin X: RASSF10 is epigenetically inactivated and suppresses cell proliferation and induces cell apoptosis by activating the p53 signalling pathway in papillary thyroid carcinoma cancer. Cell Physiol Biochem. 41:1229–1239. 2017. View Article : Google Scholar : PubMed/NCBI
30	Figiel S, Vasseur C, Bruyere F, Rozet F, Maheo K and Fromont G: Clinical significance of epithelial-mesenchymal transition markers in prostate cancer. Hum Pathol. 61:26–32. 2017. View Article : Google Scholar : PubMed/NCBI
31	Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, et al: Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status. Cancer Res. 79:1658–1670. 2019. View Article : Google Scholar : PubMed/NCBI
32	Das V, Bhattacharya S, Chikkaputtaiah C, Hazra S and Pal M: The basics of epithelial-mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective. J Cell Physiol. Feb 5–2019.(Epub ahead of print). View Article : Google Scholar
33	Zhang C and Wang Y: Metformin attenuates cells stemness and epithelial-mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β-catenin pathway. Mol Med Rep. 19:1203–1209. 2019.PubMed/NCBI
34	He J, Zhou M, Chen X, Yue D, Yang L, Qin G, Zhang Z, Gao Q, Wang D, Zhang C, et al: Inhibition of SALL4 reduces tumorigenicity involving epithelial-mesenchymal transition via Wnt/β-catenin pathway in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 35:982016. View Article : Google Scholar : PubMed/NCBI